Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass
graft (CABG) surgery, and often requires patients to go on dialysis. In patients needing
dialysis, the risk of dying is very high.There are no known therapies to reduce the chance of
developing kidney damage after heart surgery. There is evidence that patients with high
levels of a substance called ouabain have an increased risk of developing kidney damage. This
study is testing the hypothesis that giving a medication called DigiFab to lower the ouabain
levels will reduce the risk of developing kidney damage after heart surgery.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Treatments:
Antibodies Digoxin Immunoglobulin Fab Fragments Immunoglobulins Ouabain